Navigation Links
Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
Date:7/9/2012

CAMBRIDGE, Mass., July 10, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical hold on clinical trials evaluating the safety and efficacy of IB1001, an intravenous recombinant factor IX (rFIX) being investigated for the treatment and prevention of bleeding episodes in people with hemophilia B. 

The clinical hold impacts two ongoing IB1001 clinical trials – a phase 3 study evaluating the safety and efficacy of IB1001 to treat and prevent bleeding episodes in adults with hemophilia B, and a phase 3/3b study evaluating the safety and efficacy of IB1001 to treat and prevent bleeding episodes in previously treated pediatric subjects with hemophilia B. The adult study has completed its primary analysis period.

Inspiration recently reported to the FDA that, during the course of routine laboratory evaluations conducted as part of an ongoing phase 3 clinical trial, the Company discovered that a higher proportion of individuals treated with IB1001 have developed antibodies to proteins from the Chinese hamster ovary, or CHO, host cells used to manufacture the therapy than was expected based on earlier study data. Inspiration has notified clinical sites in the U.S. to hold treatment of patients with IB1001. Inspiration is also sharing the FDA directive with regulators in countries outside of the U.S. where the studies are being conducted.

Small amounts of host cell protein are expected and documented in recombinant therapeutic products of all types. Nevertheless, the higher than expected rate of anti-CHO antibody development in people treated with IB1001 has led Inspiration to initiate a thorough investigation.

A total of 86 people with hemophilia B have received IB1001 in clinical studies and, to date, no adverse events related to the development of antibodies to CHO protein have been reported. Furthermore, no relationship has been observed between the development of anti-CHO protein reactivity and the development of any antibodies to factor IX. Inspiration continues to follow subjects enrolled in clinical trials of IB1001 to collect safety-related information and will share this information with regulators.

"As always, the safety of participants in our clinical programs is our primary concern. We are conducting a full investigation into the root cause of these antibodies," said John P. Butler, Chief Executive Officer of Inspiration. "We have already made progress in identifying potential options to reduce antibody formation and will continue to work with the FDA on plans to move the IB1001 program forward. At Inspiration we are committed to developing the best possible treatment options for people with hemophilia, and this commitment drives our IB1001 program."

About Inspiration BiopharmaceuticalsAs the only biopharmaceutical company dedicated solely to hemophilia, Inspiration is committed to improving the care of people with this condition by broadening treatment choices, expanding global access to care, and advancing innovative therapies.  Founded by two families whose sons have hemophilia, Inspiration is inspired to make a difference in the lives of people impacted by hemophilia around the world.

Inspiration's lead product candidates include IB1001 and OBI-1, a recombinant porcine factor VIII (FVIII) being investigated for the treatment of serious bleeds in patients with congenital hemophilia A with inhibitors or acquired hemophilia A.

For more information about Inspiration Biopharmaceuticals, please visit www.inspirationbio.com.Contacts:Inspiration Biopharmaceuticals Inc.MediaCompanyKate Lewis

Gordon H. BusenbarkFeinstein Kean Healthcare

Senior Vice President, Chief Financial Officer Tel: +1-617-761-6750

Tel: +1-617-588-1802 Email: kate.lewis@fkhealth.com
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
2. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/20/2017)... , April 20, 2017 Research ... America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, ... Segment Forecasts, 2014 - 2025" report to their offering. ... The Latin American ... 21.0 billion by 2025 Low drug registration cost ...
(Date:4/19/2017)... -- The Mobile X-Ray product segment is the most attractive ... forecast period Mobile X-Ray segment is the largest ... devices market, which is estimated to be valued at more ... of 7% over the forecast period. Mobile X-Ray segment is ... 100 Mn in 2017 over 2016. The segment,s revenue in ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the ... for lab operators and management to assess these processes with a critical eye—particularly ... unnecessary actions. , Created with the help of both internal and external ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... clearly shows that over the last decade, student well-being has seriously declined. "When ... boxes of formal education, join the Islamic State to turn the historic multi-ethnic ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation ... former Chairman of the Board of Directors for CONTACT USA, and former member of ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... Gallardo, DDS, PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium ... , The Oral Reconstruction Foundation will present its annual Global Symposium at the ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... brands, work wear distributors and International relief organizations across the globe to provide ... also offers lifestyle and work wear collections via insectshield.com . In the ...
Breaking Medicine News(10 mins):